Role of claudin-6 in high-grade endometrial carcinoma: Implications for risk stratification and personalized treatment strategies
Abstract
on the role of claudin-6 (CLDN6) in high-grade endometrial carcinoma, addressing a significant gap in current knowledge. Their research reveals that overexpression of CLDN6 is linked to unfavorable pathological features. Moreover, multivariate analysis establishes CLDN6 as an independent predictor of disease-free survival, with a hazard ratio of 68.98. These results highlight the promise of CLDN6 in improving risk stratification and as a potential therapeutic target, especially with the development of CLDN6-directed antibody-drug conjugates. To advance CLDN6 towards clinical application, further validation in prospective patient cohorts and studies exploring its interactions with other molecular pathways are essential.
Fields of Study & Subjects
Endometrial and Cervical Cancer Treatments
Breast Cancer Treatment Studies
Gastric Cancer Management and Outcomes
Publication details
- Journal / source
- World Journal of Clinical Oncology
- Volume
- 17
- Issue
- 2
- Pages
- 116390–116390
- Publication date
- 6 February 2026
- Language
- EN